Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX Inventory
Cash effect of the change in inventory; building inventory consumes cash.
Nanobiotix S.A.NASDAQ: NBTX
Inventory · Q4 FY2025 · quarter ended Dec 2025
Inventory outflow grows to €0
Q4 FY2025 inventory was €0, compared with €0 a year earlier.
Context
- Inventory amounted to 0.0% of revenue in FY2025.
- Inventory increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Inventory history
EUR · from the cash flow
- Latest · FY2025
- 0 EUR
- Year-over-year change
- —
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Inventory vs competitors
How NBTX compares with its peers on the latest reported figures
- Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
- Inventory amounts to 0.0% of revenue for NBTX, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.96M USD | +614.9% | — | 13.8% | |
| LTM Sep 2026 | $14.56M USD | +206.8% | — | 8.0% | |
| LTM Mar 2026 | $430K USD | — | — | 0.6% | |
| LTM Mar 2026 | $58K USD | +103.5% | +7.5% | 0.0% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding NBTX) | — | +206.8% | +7.5% | 4.3% | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Depreciation & Amortization | 1.56M | 1.5M | 1.51M | 1.62M | 1.5M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3K |
| Stock-Based Compensation | 3.2M | 3.17M | 3.3M | 4.3M | 3.54M |
| Change in Working Capital | (4.7M) | (606K) | (367K) | 131K | (3.4M) |
| Accounts Receivables | 62K | (101K) | (806K) | (2.07M) | 1.85M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (4.76M) | (505K) | 439K | 2.2M | (5.25M) |
| Other Non-Cash Items | 17.07M | 15.87M | 22.78M | 42.53M | (11.1M) |
| Operating Cash Flow | (29.87M) | (37.1M) | (12.48M) | (19.55M) | (33.42M) |
| Capital Expenditures | (228K) | (92K) | (328K) | (846K) | (546K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (14K) | 230K | (21K) | (109K) | (40K) |
| Investing Cash Flow | (242K) | 138K | (349K) | (955K) | (578K) |
| Debt Repayment | (3.74M) | (4.74M) | (3.62M) | (4.16M) | 38.19M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.44M) | (916K) | 50.39M | (980K) | (2.31M) |
| Financing Cash Flow | (5.18M) | (5.65M) | 46.77M | (5.14M) | 37.42M |
| Effect of Forex Changes | 64K | 83K | (51K) | 94K | (402K) |
| Net Change in Cash | (35.23M) | (42.53M) | 33.9M | (25.55M) | 3.01M |
| Free Cash Flow | (30.1M) | (37.2M) | (12.8M) | (20.4M) | (33.97M) |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.